See more : Tamtron Group Oyj (TAMTRON.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Universal Vision Biotechnology Co., Ltd. (3218.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Universal Vision Biotechnology Co., Ltd., a leading company in the Healthcare industry within the Healthcare sector.
- WESCO International, Inc. (WCC) Income Statement Analysis – Financial Results
- C3is Inc. (CISS) Income Statement Analysis – Financial Results
- DSW Capital plc (DSW.L) Income Statement Analysis – Financial Results
- Sinyi Realty Inc. (9940.TW) Income Statement Analysis – Financial Results
- Cannon Resources Limited (CNR.AX) Income Statement Analysis – Financial Results
Universal Vision Biotechnology Co., Ltd. (3218.TWO)
About Universal Vision Biotechnology Co., Ltd.
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinic provides laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting. In addition, it engages in the provision of optometric, hospital management, and technical consultancy services; and sales and leasing of medical devices. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 4.08B | 3.49B | 2.63B | 2.05B | 1.42B |
| Cost of Revenue | 1.63B | 1.35B | 995.36M | 785.99M | 601.91M |
| Gross Profit | 2.45B | 2.14B | 1.64B | 1.27B | 817.07M |
| Gross Profit Ratio | 59.98% | 61.24% | 62.18% | 61.72% | 57.58% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 427.67M | 398.41M | 314.04M | 234.16M | 210.23M |
| Selling & Marketing | 704.49M | 652.74M | 553.55M | 436.47M | 359.99M |
| SG&A | 1.13B | 1.05B | 867.59M | 670.63M | 570.02M |
| Other Expenses | 0.00 | 17.60M | 3.66M | 11.71M | 0.00 |
| Operating Expenses | 1.14B | 1.05B | 867.59M | 670.63M | 557.75M |
| Cost & Expenses | 2.77B | 2.41B | 1.86B | 1.46B | 1.16B |
| Interest Income | 19.16M | 6.93M | 4.07M | 4.84M | 7.90M |
| Interest Expense | 15.83M | 13.56M | 13.16M | 10.94M | 12.19M |
| Depreciation & Amortization | 446.15M | 372.25M | 319.52M | 263.96M | 125.66M |
| EBITDA | 1.78B | 1.49B | 1.10B | 877.04M | 372.70M |
| EBITDA Ratio | 43.62% | 42.52% | 41.65% | 42.72% | 26.27% |
| Operating Income | 1.31B | 1.11B | 776.59M | 613.08M | 247.04M |
| Operating Income Ratio | 32.14% | 31.86% | 29.51% | 29.86% | 17.41% |
| Total Other Income/Expenses | 6.73M | -21.21M | -5.75M | -10.95M | 8.00M |
| Income Before Tax | 1.32B | 1.09B | 763.11M | 602.13M | 255.04M |
| Income Before Tax Ratio | 32.30% | 31.26% | 29.00% | 29.33% | 17.97% |
| Income Tax Expense | 254.56M | 223.98M | 152.45M | 117.98M | 63.32M |
| Net Income | 1.05B | 850.53M | 595.43M | 483.21M | 238.01M |
| Net Income Ratio | 25.60% | 24.34% | 22.62% | 23.54% | 16.77% |
| EPS | 12.34 | 10.04 | 7.03 | 5.71 | 2.81 |
| EPS Diluted | 12.31 | 10.02 | 7.02 | 5.70 | 2.80 |
| Weighted Avg Shares Out | 84.73M | 84.73M | 84.72M | 84.72M | 84.72M |
| Weighted Avg Shares Out (Dil) | 84.89M | 84.86M | 84.83M | 84.86M | 84.94M |
Source: https://incomestatements.info
Category: Stock Reports